Sanford C. Bernstein Reiterates €52.00 Price Target for Fresenius SE & Co KGaA (FRA:FRE)

Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €52.00 ($60.47) target price by Sanford C. Bernstein in a research note issued on Tuesday, Borsen Zeitung reports. The firm currently has a “neutral” rating on the stock. Sanford C. Bernstein’s price target indicates a potential upside of 8.97% from the stock’s previous close.

FRE has been the subject of a number of other reports. Berenberg Bank set a €74.80 ($86.98) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Tuesday, October 29th. Nord/LB set a €58.00 ($67.44) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Tuesday, October 29th. DZ Bank restated a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Monday, November 4th. Warburg Research set a €65.00 ($75.58) target price on shares of Fresenius SE & Co KGaA and gave the stock a “buy” rating in a report on Tuesday, October 29th. Finally, Independent Research set a €51.00 ($59.30) target price on shares of Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Ten analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of €55.84 ($64.94).

FRA:FRE traded down €0.27 ($0.31) during trading hours on Tuesday, reaching €47.72 ($55.49). 1,115,381 shares of the company’s stock were exchanged. Fresenius SE & Co KGaA has a 12 month low of €60.16 ($69.95) and a 12 month high of €80.00 ($93.02). The business’s 50-day simple moving average is €44.42 and its two-hundred day simple moving average is €45.90.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.

Featured Article: Lock-Up Period Expiration

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.